Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of Ersatta in type 1 diabetes with diabetic peripheral neuropathy
2012-001246-17Phase 2Completed
- Sponsor
- Cebix
- Start
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing Ersatta with Placebo (2 arms). Primary endpoint: Bilateral change from baseline to 52 weeks in initial sensory nerve conduction velocity in the sural nerve. Started Dec 2012; status: completed.
02
Drugs
Pegylated synthetic human C-peptide
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2012-001246-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001246-17.